Global Blood Therapeutics
171 Oyster Point Blvd., Suite 300
South San Francisco
California
94080
United States
Tel: (650) 741-7700
Website: http://www.globalbloodtx.com/contact/
Email: info@globalbloodtx.com
About Global Blood Therapeutics
Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. GBT’s lead product candidate is voxelotor (formerly known as GBT440), an oral, once-daily therapy that modulates hemoglobin’s affinity for oxygen, which the company believes inhibits hemoglobin polymerization in sickle cell disease.
92 articles with Global Blood Therapeutics
-
New Year, fresh start? Could be. WalletHub recently compared more than 180 cities across the U.S., using 30 key indicators to evaluate their job strength. Some of those factors were job opportunities, employment growth, monthly average starting salary and employment outlook.
-
It's a new year! Is one of your New Year's resolutions to find a new job? Jump start your job search now and check out top companies who are looking for quality candidates in 2019!
-
EvaluatePharma and Vantage recently released their Vantage 2019 Preview which looks at the current year’s biopharma market and makes projections about the upcoming year.
-
Winter and the Holidays are right around the corner, but don't stop your job search! Check out the top companies who are looking for candidates like you right now!
-
At the American Society of Hematology meeting, companies are racing to develop a treatment for SCD, which is an inherited disorder caused by a genetic mutation in the beta-chain of hemoglobin. Some of the data presented by companies were promising, while others reported setbacks.
-
The American Society of Hematology is holding its 60th Annual Meeting & Exposition starting December 1 and running through December 4 in San Diego. Most of the players, big and small, in cancer drug therapies will be there, presenting updates and breaking stories about their hematology pipelines.
-
Toward the end of every year, biopharma executives are asked to dust off their crystal balls and predict what the next year might reveal. It’s that time of year again! Find out what execs are saying about M&A, gene therapy, sickle cell, and more.
-
GBT Announces Upcoming Presentations at National Sickle Cell Disease Association of America (SCDAA) Convention
10/4/2018
Global Blood Therapeutics, Inc. today announced that three abstracts related to its sickle cell disease (SCD) development programs, including voxelotor, have been accepted for oral presentation during the 46th Annual National Sickle Cell Disease Association of America (SCDAA) Convention in Baltimore, MD, taking place October 10-13, 2018.
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Global Blood Therapeutics, Inc. - GBT
9/13/2018
Pomerantz LLP is investigating claims on behalf of investors of Global Blood Therapeutics, Inc.
-
GBT Appoints Heidi L. Wagner as Senior Vice President, Government Affairs and Policy
8/21/2018
Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced the appointment of Heidi L. Wagner as senior vice president, government affairs and policy. Ms. Wagner joins GBT from Alexion Pharmaceuticals, where she was senior vice president, global government affairs.
-
Martin Shkreli has been blogging about the biopharma industry from prison.
-
This week had a few disappointing clinical trials, as do most weeks, but it also had a number of significant successes. Here’s a look at some of the clinical trials that met their primary endpoints this week.
-
Global Blood Therapeutics (GBT) reported the results of a review of Part A of its Phase III HOPE (Hemoglobin Oxygen Affinity Modulation to Inhibit HbS PolymErization) Study of voxelotor for sickle cell disease.
-
Most investors thought 2018 would be a big year for mergers and acquisitions in the biopharma industry because of changes to the tax law, and so far they’ve been right.
-
The BTD decision for voxelotor was based on clinical data submitted from a trio of studies.
-
GBT Appoints Wendy L. Yarno to Board of Directors
12/22/2017
Ms. Yarno has more than 25 years of experience in the biopharmaceutical industry, including serving as chief marketing officer at Merck.
-
Bay Area's Global Blood Therapeutics Prices a $100M Common Stock Public Offering
12/15/2017
Cantor Fitzgerald & Co. is the sole book-running manager for the offering.
-
GBT Announces Presentation of Six Studies at ASH Supporting Voxelotor Sickle Cell Disease (SCD) Program
12/11/2017
The data were presented in oral and poster sessions during the 59th American Society of Hematology (ASH) Annual Meeting & Exposition at the Georgia World Congress Center in Atlanta.
-
GBT Announces New Phase IIa Data at ASH for Voxelotor in Adolescents With Sickle Cell Disease (SCD)
12/11/2017
The HOPE-KIDS 1 Study is an ongoing open-label, single- and multiple-dose study evaluating the safety, tolerability, pharmacokinetics and exploratory treatment effect of voxelotor in a pediatric population with SCD.
-
Global Blood Therapeutics Announces New Employment Inducement Grants - Dec. 1, 2017
12/1/2017
The first employee received an option to purchase 15,000 shares of the Company’s common stock with a per share exercise price of $39.25, the closing trading price on the grant date of November 28, 2017.